First Targeted Therapy for Glioma Headed for FDA Approval
A first-in-class targeted therapy for low-grade glioma could gain FDA approval as early as spring 2024. Here are three things you should know about the emerging drug “vorasidenib.”
Sign up for our bi-monthly email to get the latest news on treatments, support, and stories from the brain tumor community.
A first-in-class targeted therapy for low-grade glioma could gain FDA approval as early as spring 2024. Here are three things you should know about the emerging drug “vorasidenib.”
**Sponsored Content**
After processing the initial shock of her GBM diagnosis at 36, Jeanneane M. created a “coping routine” that’s helped her get through difficult days and hold onto hope for her future.
Family and friends of Kelli McLaughlin are doing the hardest things: turning their grief into action to carry on Kelli’s legacy and vision of a future without brain tumors.
Discover how you can play a role in the ABTA’s five-year campaign “Meet Hope Head On.”
Join a free, half-day virtual meeting for patients and families dealing with brain metastases, led by Priya Kumthekar, MD, Director of the Brain Metastases Program at Northwestern University.
Register now for the nation’s largest patient-centric brain tumor conference, returning to Chicago and online this September.
**Sponsored Content** Meet one neurosurgeon who hopes to transform brain tumor care by bringing state-of-the-art technology to his homeland of Puerto Rico.
Gather friends and family to raise awareness and critical funds at a BT5K Run & Walk event near you.
**Sponsored Content** Advancements in brain tumor treatments are made possible by patients who volunteer to participate in clinical trials.
Always free for patients & caregivers
American Brain Tumor Association
8550 W. Bryn Mawr Ave. Ste 550
Chicago, IL 60631